Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib plus interleukin-2 versus sorafenib alone as first-line therapy for metastatic renal cell carcinoma
2006-003137-32Phase 2Completed
- Sponsor
- ITMO University
- Start
- Jun 2007
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in renal cell carcinoma (RCC) comparing Sorafenib + aldesleukin with Sorafenib alone (2 arms). Primary endpoint: Progression-free survival. Started Jun 2007; status: completed.
02
Drugs
sorafenibaldesleukin
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2006-003137-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003137-32.